Relonchem Limited receives UKMHRA Marketing Authorization for its products

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE:MARKSANS; BSE: 524404) announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization from UKMHRA for the below mentioned products:

1) Rasagiline Relonchem 1 mg Tablets
2) Olmesartan 10 mg Film-coated Tablets
3) Olmesartan 20 mg Film-coated Tablets
4) Olmesartan 40 mg Film-coated Tablets

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 166.25 as compared to the previous close of Rs. 166.60. The total number of shares traded during the day was 155769 in over 2672 trades.

The stock hit an intraday high of Rs. 168.60 and intraday low of 164.75. The net turnover during the day was Rs. 25953112.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Relonchem UKMHRA MarketingAuthorization 4Products